List of Excipients in Branded Drug LIDOCAINE 5%

Generic Drugs Containing LIDOCAINE 5%

Company	Ingredient	NDC	Excipient
ATLANTIC BIOLOGICALS CORP	lidocaine 5% cream	17856-0028	POLYETHYLENE GLYCOL 1450
ATLANTIC BIOLOGICALS CORP	lidocaine 5% cream	17856-0028	POLYETHYLENE GLYCOL 300
Rhodes Pharmaceuticals LP	lidocaine 5%	42858-118	CARBOXYMETHYLCELLULOSE SODIUM
Rhodes Pharmaceuticals LP	lidocaine 5%	42858-118	DIHYDROXYALUMINUM AMINOACETATE

What are the Most Frequently-Used Excipients in LIDOCAINE 5%?

# Of NDCs	Excipient
9	CARBOXYMETHYLCELLULOSE SODIUM
1	CELLULOSE GUM
10	DIHYDROXYALUMINUM AMINOACETATE
10	EDETATE DISODIUM

# Lidocaine 5% Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Lidocaine 5% is a mature local-anesthetic platform with limited active-ingredient differentiation. Commercial value depends on dosage form, excipient selection, delivery performance, patient convenience, and regulatory positioning. The strongest opportunities are in transdermal systems, low-irritancy semisolids, long-wear products, preservative optimization, and combination products rather than in a conventional 5% ointment.

The main commercial formats are:

Dosage form	Representative product	Primary use	Excipient-driven differentiation
Transdermal patch	Lidoderm and authorized/generic equivalents	Post-herpetic neuralgia and localized neuropathic pain	Adhesion, drug release, wear time, skin tolerability
Ointment	Lidocaine 5% ointment, including Xylocaine Ointment	Mucosal anesthesia, minor procedures, anorectal conditions	Solubilization, spreadability, mucosal retention, preservative strategy
Cream	Compounded and marketed topical products	Local skin anesthesia and dermatologic procedures	Emulsion stability, cosmetic feel, penetration control
Gel or jelly	Lidocaine 5% topical jelly	Mucosal anesthesia, catheterization, endoscopy	Mucoadhesion, lubrication, rapid anesthetic onset
Spray or aerosol	Lower-strength products are more common	Surface anesthesia	Solvent system, spray plume, dose uniformity
Film, foam, or hydrogel	Emerging and specialty formats	Localized pain and procedural anesthesia	Controlled delivery, cooling, convenience, reduced residue

What is the FDA status of lidocaine 5% products?

Lidocaine is an FDA-approved local anesthetic with extensive use across prescription, over-the-counter, hospital, dental, and compounded settings. The regulatory pathway depends on the dosage form and intended use.

Transdermal patch status

Lidoderm, a 5% lidocaine patch, was approved by the FDA under NDA 020612 for relief of pain associated with post-herpetic neuralgia. Each patch contains 700 mg of lidocaine in an adhesive system, although only a portion of the drug is delivered during the labeled wear period.[1]

Generic lidocaine 5% patches have been approved through the ANDA pathway. Generic competition has reduced the value of the original branded product, but the market remains commercially relevant because the patch format provides a differentiated delivery system.

Semisolid and mucosal products

Lidocaine 5% ointments and jellies have been marketed for topical and mucosal anesthesia. The regulatory status varies by product, indication, manufacturer, and application. Some products are approved drug products, while others are compounded under applicable pharmacy or outsourcing-facility rules.

A sponsor developing a new 5% cream, ointment, or gel must establish the applicable regulatory pathway. A generic product may require pharmaceutical equivalence, bioequivalence or comparative performance data, and compliance with FDA requirements for the relevant dosage form. A new indication or materially different delivery system may require a 505(b)(2) application.

What excipients are used in lidocaine 5% formulations?

The excipient strategy depends on whether the objective is solubilization, controlled release, skin penetration, adhesion, lubrication, preservation, or mucosal residence.

Common excipient classes

Excipient class	Examples	Formulation purpose	Key development issue
Oily vehicles	Mineral oil, petrolatum, polyethylene glycol ointment bases	Occlusion, spreadability, drug suspension	Greasiness, drug release, difficult wash-off
Polyethylene glycols	PEG 400, PEG 3350, PEG-based ointment bases	Solubilization, water miscibility, texture	Osmolality, irritation, crystallization
Emulsifiers	Polysorbates, glyceryl stearate, cetostearyl alcohol	Cream stability and texture	Sensitization, emulsion failure
Humectants	Propylene glycol, glycerin	Moisture retention and co-solvency	Stinging, increased permeation
Penetration enhancers	Propylene glycol, ethanol, oleic acid, isopropyl myristate	Increased skin flux	Irritation and systemic exposure
Gelling agents	Carbomers, cellulose derivatives, poloxamers	Viscosity and residence time	Neutralization, drug release, microbial control
Mucoadhesive polymers	Carbomer, polycarbophil, alginates, hydroxypropyl cellulose	Mucosal retention	Residue, patient acceptability
Adhesives	Acrylics, silicones, polyisobutylene	Patch attachment	Skin stripping, heat, moisture sensitivity
Preservatives	Methylparaben, propylparaben, phenoxyethanol, benzyl alcohol	Microbial control	Allergy, compatibility, regulatory scrutiny
Antioxidants and chelators	Tocopherol, sodium metabisulfite, EDTA	Stability management	Sensitivity and formulation compatibility
Buffers	Citrate, phosphate, tromethamine	pH control	Mucosal irritation and lidocaine ionization

Lidocaine is a weak base with pKa near 7.9. The un-ionized fraction is more capable of crossing lipid-rich biological barriers, while the ionized fraction is generally more water-soluble. Formulators therefore must balance pH, solubility, skin flux, local tolerability, and chemical stability.

Which excipient strategy is strongest for a lidocaine 5% patch?

For a transdermal patch, the commercial objective is controlled local delivery with reliable adhesion and limited systemic exposure. The best excipient strategy is usually a drug-in-adhesive or polymer-matrix design that avoids a complex reservoir architecture.

Adhesive selection

Acrylic adhesives can provide strong adhesion and broad compatibility with polar and moderately lipophilic ingredients. Silicone adhesives generally offer better breathability and reduced interaction with some active ingredients, but they can provide lower initial tack. Polyisobutylene systems may offer stable adhesion and relatively simple manufacturing.

The selection should be based on:

• Drug crystallization during shelf life.
• Adhesion after sweating or bathing.
• Removal force and skin residue.
• Delivery uniformity across the patch.
• Compatibility with backing and release-liner materials.
• Adhesion after repeated application to fragile or aged skin.

High-value patch improvements

Commercially defensible improvements include:

1. A smaller patch with equivalent analgesic exposure.
2. Longer wear time without increased systemic exposure.
3. Better adhesion in humid or active-use conditions.
4. Reduced skin irritation and lower removal force.
5. A flexible patch for joints, ribs, feet, or other contoured sites.
6. A transparent or cosmetically discreet product.
7. A reusable or multi-day delivery system, if safety and dose control support the design.
8. Packaging that improves moisture protection and unit-dose handling.

A smaller, thinner patch can create meaningful commercial differentiation because the reference product requires several patches in some treatment regimens. A design that reduces bulk while preserving local efficacy may support premium pricing even in a genericized market.

What excipients are best for lidocaine 5% ointment and cream?

Ointment strategy

An ointment is suitable when prolonged contact, occlusion, or mucosal application is important. Petrolatum-based systems can provide strong occlusion and low water activity. PEG ointments can improve water washability and may support higher apparent solubility.

The principal formulation risks are:

• Slow drug release from highly occlusive bases.
• Lidocaine crystallization during storage.
• Poor patient acceptance because of greasiness.
• Inconsistent dosing from tube extrusion.
• Limited compatibility with latex or medical devices.
• Preservative requirements where water is present.

A commercial ointment opportunity exists in a low-residue, non-greasy 5% system with improved wash-off and consistent dose per application. A clear or translucent ointment can also improve consumer perception, provided the formulation remains physically stable.

Cream strategy

A cream can provide a more acceptable cosmetic profile than an ointment. Oil-in-water emulsions are easier to wash off, while water-in-oil emulsions may provide greater occlusion and longer residence.

Propylene glycol can act as both a humectant and cosolvent, but high concentrations may produce burning or erythema, particularly on damaged skin. Alcohol-containing systems may increase onset but can cause stinging. The commercial opportunity is therefore a balanced emulsion that provides adequate release without relying on aggressive penetration enhancers.

A cream formulation may be positioned for:

• Minor dermatologic procedures.
• Localized neuropathic pain.
• Hemorrhoidal or perianal discomfort.
• Pediatric or geriatric use where low stinging is important.
• Clinic and ambulatory-procedure kits.

Any pediatric positioning requires careful dose-control design because large-area application, occlusion, damaged skin, or repeated dosing can increase systemic exposure.

How do formulation patents protect lidocaine 5% products?

The basic composition of matter for lidocaine is long expired. Protection must therefore come from formulation, device, manufacturing, indication, or commercial execution.

Formulation patent opportunities

Potential claim categories include:

• Specific adhesive compositions.
• Defined ratios of lidocaine to polymer or plasticizer.
• Particle-size or crystallization-control systems.
• pH and buffer ranges.
• Preservative-free aqueous gels.
• Mucoadhesive compositions with defined residence time.
• Low-irritancy penetration-enhancer systems.
• Controlled-release matrices.
• Patch backing, liner, and occlusion structures.
• Dose-metering or applicator mechanisms.
• Stability profiles under defined temperature and humidity conditions.

A patent that claims only “lidocaine 5% in a cream” is likely to face substantial novelty and obviousness challenges. Stronger protection links the composition to measurable performance, such as adhesive retention, reduced crystallization, controlled flux, lower skin irritation, or a defined pharmacokinetic profile.

Method-of-use patents

Method-of-use protection may target:

• Post-herpetic neuralgia.
• Localized neuropathic pain.
• Painful diabetic neuropathy.
• Osteoarthritis-related focal pain.
• Procedural anesthesia.
• Mucosal anesthesia.
• Reduction of pain from injections or dermatologic procedures.

A method patent is stronger when the treatment protocol has a specific patient population, application schedule, anatomical site, dose limit, or clinically measurable outcome. Broad pain-treatment claims face greater prior-art exposure.

When does lidocaine 5% lose exclusivity?

The active ingredient has no meaningful remaining composition-of-matter exclusivity. The original Lidoderm patch estate also no longer provides a conventional branded monopoly. Generic lidocaine 5% patches are available, and semisolid lidocaine products have long faced generic, hospital, OTC, and compounding competition.

Protection category	Current commercial position
Lidocaine composition of matter	Expired
Original branded patch exclusivity	Expired
Core patch patents	Generally expired or no longer a practical barrier to ordinary generic entry
Product-specific formulation patents	May remain relevant if claims are unexpired and enforceable
Method-of-use patents	Potentially relevant for narrow indications
Regulatory exclusivity	Product- and indication-specific; no broad market exclusivity should be assumed
Trade secrets	Relevant to adhesive processing, scale-up, coating, and stability control

The absence of active-ingredient exclusivity shifts value toward manufacturing know-how, device performance, brand recognition, distribution, and differentiated clinical labeling.

What generic entry risks exist for lidocaine 5%?

Generic entry risk is high for conventional ointments, creams, jellies, and patches. The principal barriers are not usually patent barriers but technical and regulatory requirements.

Patch-specific barriers

A generic patch sponsor must address:

• Adhesion performance.
• Drug release and delivery rate.
• Residual drug content.
• Peel and shear properties.
• Skin irritation and sensitization.
• Extractables and leachables.
• Stability of the adhesive matrix.
• Dose uniformity across the patch.
• Packaging protection from heat and humidity.

These requirements create more development complexity than a standard tablet generic. They do not eliminate competition, but they can slow entry and support a modest price premium for reliable products.

Semisolid entry barriers

For creams and ointments, the main risks are:

• Formulation sameness or comparative performance.
• Drug release from the vehicle.
• Microbial limits and preservative effectiveness.
• Physical stability.
• Dose uniformity.
• Container-closure compatibility.
• Patient acceptability.

A sponsor with a novel vehicle may avoid direct commoditization, but it may also require a more expensive 505(b)(2) strategy.

Which commercial opportunities exist for lidocaine 5%?

Premium transdermal products

The most attractive opportunity is a next-generation patch that improves adhesion, comfort, size, wear time, or application flexibility. The product should generate objective comparative data rather than rely on a different excipient list alone.

Mucosal and procedural products

A fast-acting, low-sting gel or jelly with improved residence time can target dental, urology, gastroenterology, dermatology, and outpatient-procedure markets. Metered applicators and prefilled unit doses can improve dose control and reduce contamination.

Preservative-free products

Preservative-free single-use tubes, syringes, sachets, or applicators may appeal to hospitals and patients with sensitivity concerns. The packaging cost is higher, but the product can target procedural settings where sterility, convenience, and reduced cross-contamination have commercial value.

Combination products

Potential combinations include lidocaine with:

• Antiseptics for procedural preparation.
• Anti-inflammatory agents for localized inflammatory pain.
• Antipruritics for dermatologic conditions.
• Hemorrhoidal ingredients for anorectal products.
• Other local anesthetics for broader or faster anesthesia.

Combination products face clinical, regulatory, and safety complexity. Each active ingredient must contribute to the labeled therapeutic effect, and the combination must not create unacceptable systemic exposure.

Specialty delivery systems

Hydrogel films, bioadhesive films, foams, and dissolving systems can create new product categories. Their value depends on whether they improve patient outcomes or clinical workflow. A novel dosage form without a clear benefit will remain vulnerable to low-cost cream and ointment alternatives.

How does lidocaine 5% compare with competing local anesthetics?

Product class	Relative strength	Typical commercial advantage	Main limitation
Lidocaine 5%	Established, rapid local anesthetic	Familiarity, broad clinical use, extensive safety history	Mature competition and systemic toxicity risk
Benzocaine	Surface anesthesia	OTC familiarity and low cost	Methemoglobinemia concern and limited penetration
Prilocaine	Local anesthesia	Often used in combination with lidocaine	Slower onset in some applications and methemoglobinemia concern
Tetracaine	Potent local anesthesia	Useful for certain mucosal and ophthalmic applications	Greater toxicity concerns
Dibucaine	Potent topical anesthetic	Long duration in selected products	Narrower use and toxicity concerns
Lidocaine-prilocaine combination	Broad topical anesthesia	Established procedural positioning	More complex formulation and labeling

Lidocaine remains attractive because of its established clinical profile and formulation flexibility. Its weakness is that most simple product concepts can be copied or substituted.

What is the patent strength of a new lidocaine 5% product?

Patent strength is likely to be moderate for a well-defined delivery system and weak for a conventional semisolid.

Product concept	Likely patent strength	Commercial defensibility
Conventional 5% petrolatum ointment	Low	Low
Standard oil-in-water cream	Low to moderate	Low to moderate
Preservative-free unit-dose gel	Moderate	Moderate
Mucoadhesive controlled-residence gel	Moderate to high	Moderate to high
Low-profile, long-wear patch	Moderate to high	High if performance is demonstrated
Novel adhesive matrix with anti-crystallization system	High potential	High if claims survive validity challenges
Combination product with established actives	Moderate	Dependent on clinical differentiation
Metered-dose applicator with ordinary formulation	Moderate device protection	Moderate

The strongest estate would combine composition claims, manufacturing-process claims, device claims, and method-of-use claims. Geographic coverage should prioritize the United States, European Union, United Kingdom, Japan, Canada, Australia, South Korea, and major emerging markets with meaningful topical-anesthetic demand.

What manufacturing and IP barriers matter most?

Manufacturing capability can provide more practical protection than patents. Relevant barriers include:

• Uniform coating of drug-containing adhesive layers.
• Control of residual solvents.
• Prevention of lidocaine crystallization.
• Reproducible patch cutting and die handling.
• Low-defect packaging.
• Preservation of microbial quality in aqueous semisolids.
• Consistent viscosity and extrusion force.
• Scale-up without changing drug release.
• Stability under high temperature and humidity.
• Compatibility between formulation, tube, liner, backing, and applicator.

A company with validated transdermal coating and packaging capacity may gain a cost and quality advantage even where patent protection is limited.

What licensing opportunities exist for lidocaine 5%?

Licensing targets include:

1. Adhesive or polymer technologies that improve wear time.
2. Mucoadhesive platforms with established regulatory history.
3. Preservative-free packaging systems.
4. Metered applicators and unit-dose delivery devices.
5. Clinical rights for niche indications.
6. Regional distribution rights for hospital and dental channels.
7. Contract manufacturing capacity for patches and sterile or low-bioburden gels.

The most valuable deal structure would link technology access to objective performance milestones, such as adhesion duration, skin irritation reduction, drug-release equivalence, or successful FDA filing. A license covering only a conventional excipient combination is unlikely to justify substantial upfront consideration.

Key Takeaways

• Lidocaine 5% is a mature active ingredient with no meaningful composition-of-matter exclusivity.
• Conventional creams, ointments, and jellies face high generic and compounding competition.
• The strongest commercial opportunity is a differentiated patch or mucosal delivery system.
• Excipient selection should focus on measurable performance: adhesion, residence time, drug release, low irritation, stability, and dose control.
• Formulation patents are more defensible when tied to technical results rather than concentration alone.
• Preservative-free unit-dose products can target hospitals, dental practices, and procedural markets.
• Manufacturing know-how may provide greater practical protection than a narrow composition patent.
• A strong IP estate should combine formulation, device, process, and method-of-use claims.
• Generic entry risk is high for ordinary products and moderate for technically complex patches.
• Commercial success will depend on delivery convenience and clinical workflow advantages, not merely the presence of a new excipient.

FAQs

Can propylene glycol be used in a lidocaine 5% formulation?

Yes. Propylene glycol can function as a cosolvent, humectant, and penetration enhancer. Its concentration must be controlled because it can increase stinging and irritation, especially on damaged skin or mucosal tissue.

Is a lidocaine 5% patch more difficult to develop than a lidocaine 5% cream?

Yes. A patch requires control of adhesive performance, drug release, residual drug, skin tolerability, packaging, and mechanical properties. A cream has fewer device-related requirements but must meet emulsion, microbial, stability, and drug-release specifications.

Can a new lidocaine 5% ointment receive patent protection?

Potentially, but a basic 5% ointment is unlikely to support strong protection. Patentability improves when the product has a novel vehicle, defined stability advantage, controlled release, mucoadhesive effect, reduced irritation, or specialized applicator.

Is lidocaine 5% suitable for a 505(b)(2) application?

It can be, particularly where the product uses a materially different dosage form, delivery system, indication, dosing regimen, or clinical positioning from an established reference product. The regulatory strategy depends on the specific formulation and claims.

What is the most attractive hospital product opportunity?

A preservative-free, unit-dose lidocaine 5% gel or ointment with a clean applicator, consistent dose delivery, low stinging, and clear procedural labeling has the strongest hospital-oriented profile.

References

1. U.S. Food and Drug Administration. (1999). Lidoderm (lidocaine patch 5%) prescribing information. Endo Pharmaceuticals.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.

4. U.S. Food and Drug Administration. (1997). Guidance for industry: SUPAC-SS, nonsterile semisolid dosage forms, scale-up and postapproval changes. FDA.

5. U.S. Food and Drug Administration. (2022). Product-specific guidances for generic drug development. FDA.

6. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

7. DailyMed. (2024). Lidocaine patch 5% and lidocaine ointment 5% labeling. National Library of Medicine.